LIGAND PHARMACEUTICALS (LGND) Stock Earnings & Estimates
USA - NASDAQ:LGND - US53220K5048 - Common Stock
165.515 USD
-0.24 (-0.14%)
164.595 USD
-0.92 (-0.56%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 196.2M -29.20% | 131.314M -33.07% | 167.133M 27.28% | 219M 31.03% | 248.08M 13.28% | 291.68M 17.57% | 349.49M 19.82% | 416.29M 19.11% | 513.21M 23.28% | 625.54M 21.89% | 763.15M 22.00% | |
| EBITDA YoY % growth | 54.5M -58.08% | 46.342M -14.97% | 58.26M 25.72% | 81.938M 40.64% | 141.47M 72.65% | 179.2M 26.67% | 222.53M 24.18% | 259.58M 16.65% | 306.06M 17.91% | N/A | N/A | |
| EBIT YoY % growth | 3M -96.20% | 9.821M 227.37% | 23.021M 134.41% | 31.599M 37.26% | 122.15M 286.56% | 131.51M 7.66% | 140.73M 7.01% | 169.32M 20.32% | 234.76M 38.65% | 247.09M 5.25% | 305.26M 23.54% | |
| Operating Margin | 1.53% | 7.48% | 13.77% | 14.43% | 49.24% | 45.09% | 40.27% | 40.67% | 45.74% | 39.50% | 40.00% | |
| EPS YoY % growth | 4.28 -33.33% | 6.10 42.52% | 5.71 -6.39% | 7.00 22.58% | 7.59 8.50% | 8.64 13.83% | 9.99 15.58% | 10.91 9.19% | 14.03 28.56% | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.96 6.51% | 2.08 64.07% | 1.52 14.65% | 1.67 4.23% | 2.14 9.29% | 2.10 0.84% |
| Revenue Q2Q % growth | 59.881M 15.57% | 63.335M 47.94% | 52.104M 14.94% | 59.037M 23.96% | 67.233M 12.28% | 70.699M 11.63% |
| EBITDA Q2Q % growth | 35.475M -5.57% | 36.929M 0.01% | 27.678M 199.24% | 36.89M 36.57% | 45.584M 28.50% | 49.463M 33.94% |
| EBIT Q2Q % growth | 26.268M 139.78% | 27.541M 1,532.54% | 9.262M 125.27% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.60 14.29% | 1.45 | 0.15 | 10.36% |
| Q1 2025 Q2Q % growth | 1.33 10.83% | 1.24 | 0.09 | 7.61% |
| Q4 2024 Q2Q % growth | 1.27 -7.97% | 1.21 | 0.06 | 4.63% |
| Q3 2024 Q2Q % growth | 1.84 80.39% | 1.37 | 0.47 | 33.98% |
| Q2 2024 Q2Q % growth | 1.40 -1.41% | 1.08 | 0.32 | 29.98% |
| Q1 2024 Q2Q % growth | 1.20 -47.37% | 0.79 | 0.41 | 50.98% |
| Q4 2023 Q2Q % growth | 1.38 1.47% | 0.67 | 0.71 | 104.76% |
| Q3 2023 Q2Q % growth | 1.02 -22.14% | 0.62 | 0.40 | 63.93% |
| Q2 2023 Q2Q % growth | 1.42 37.86% | 0.65 | 0.77 | 117.61% |
| Q1 2023 Q2Q % growth | 2.28 293.10% | 0.91 | 1.37 | 150.03% |
| Q4 2022 Q2Q % growth | 1.36 -24.44% | 1.22 | 0.14 | 11.74% |
| Q3 2022 Q2Q % growth | 1.31 -17.09% | 0.44 | 0.87 | 197.43% |
| Q2 2022 Q2Q % growth | 1.03 -36.81% | 0.44 | 0.59 | 134.84% |
| Q1 2022 Q2Q % growth | 0.58 -58.87% | 0.67 | -0.09 | -13.41% |
| Q4 2021 Q2Q % growth | 1.80 11.11% | 1.40 | 0.40 | 28.81% |
| Q3 2021 Q2Q % growth | 1.58 51.92% | 1.06 | 0.52 | 49.42% |
| Q2 2021 Q2Q % growth | 1.63 63.00% | 1.39 | 0.24 | 17.36% |
| Q1 2021 Q2Q % growth | 1.41 58.43% | 1.15 | 0.26 | 22.88% |
| Q4 2020 Q2Q % growth | 1.62 128.17% | 1.01 | 0.61 | 60.43% |
| Q3 2020 Q2Q % growth | 1.04 112.24% | 1.00 | 0.04 | 3.86% |
| Q2 2020 Q2Q % growth | 1.00 47.06% | 0.78 | 0.22 | 28.97% |
| Q1 2020 Q2Q % growth | 0.89 -23.28% | 0.67 | 0.22 | 32.87% |
| Q4 2019 Q2Q % growth | 0.71 | 0.65 | 0.06 | 8.42% |
| Q3 2019 Q2Q % growth | 0.49 | 0.62 | -0.13 | -21.25% |
| Q2 2019 Q2Q % growth | 0.68 | 0.56 | 0.12 | 21.77% |
| Q1 2019 Q2Q % growth | 1.16 | 1.04 | 0.12 | 11.50% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 47.627M 14.68% | 44.747M | 2.88M | 6.44% |
| Q1 2025 Q2Q % growth | 45.333M 46.34% | 39.476M | 5.857M | 14.84% |
| Q4 2024 Q2Q % growth | 42.812M 52.35% | 39.803M | 3.009M | 7.56% |
| Q3 2024 Q2Q % growth | 51.812M 57.64% | 41.463M | 10.349M | 24.96% |
| Q2 2024 Q2Q % growth | 41.531M 57.52% | 33.522M | 8.009M | 23.89% |
| Q1 2024 Q2Q % growth | 30.978M -29.56% | 28.482M | 2.496M | 8.76% |
| Q4 2023 Q2Q % growth | 28.101M 3.89% | 26.23M | 1.871M | 7.13% |
| Q3 2023 Q2Q % growth | 32.868M -44.50% | 27.73M | 5.138M | 18.53% |
| Q2 2023 Q2Q % growth | 26.366M -54.08% | 26.248M | 118K | 0.45% |
| Q1 2023 Q2Q % growth | 43.979M 20.42% | 34.718M | 9.261M | 26.67% |
| Q4 2022 Q2Q % growth | 27.05M -62.67% | 39.952M | -12.902M | -32.29% |
| Q3 2022 Q2Q % growth | 59.22M -8.67% | 39.043M | 20.177M | 51.68% |
| Q2 2022 Q2Q % growth | 57.42M -32.19% | 38.489M | 18.931M | 49.19% |
| Q1 2022 Q2Q % growth | 36.52M -33.78% | 37.052M | -532K | -1.44% |
| Q4 2021 Q2Q % growth | 72.47M 3.54% | 66.625M | 5.845M | 8.77% |
| Q3 2021 Q2Q % growth | 64.84M 54.93% | 56.765M | 8.075M | 14.23% |
| Q2 2021 Q2Q % growth | 84.68M 104.44% | 71.901M | 12.779M | 17.77% |
| Q1 2021 Q2Q % growth | 55.15M 66.31% | 64.112M | -8.962M | -13.98% |
| Q4 2020 Q2Q % growth | 69.99M 159.22% | 55.177M | 14.813M | 26.85% |
| Q3 2020 Q2Q % growth | 41.85M 68.68% | 45.247M | -3.397M | -7.51% |
| Q2 2020 Q2Q % growth | 41.42M 65.75% | 32.019M | 9.401M | 29.36% |
| Q1 2020 Q2Q % growth | 33.16M -23.74% | 27.064M | 6.096M | 22.52% |
| Q4 2019 Q2Q % growth | 27M | 25.588M | 1.412M | 5.52% |
| Q3 2019 Q2Q % growth | 24.81M | 23.756M | 1.054M | 4.44% |
| Q2 2019 Q2Q % growth | 24.99M | 21.434M | 3.556M | 16.59% |
| Q1 2019 Q2Q % growth | 43.48M | 40.591M | 2.889M | 7.12% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.7% | 20.84% | 12.06% | 12.37% |
| Revenue | 5.41% | 18.31% | 10.66% | 10.66% |